Mounjaro/Zepbound (tirzepatide), approved dual GLP-1/GIP agonist for type 2 diabetes and obesity Recent Highlights: In April 2026, the FDA approved orforglipron (Foundayo), making it one of the first oral GLP-1 pills that can be taken any time of day and that has no food or water restrictions
Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology
Both medicines have side effects, and both can bring about rapid weight changes
Appetite perception The effect of inulin and MDX on desire to eat ratings was comparable before surgery, although ratings significantly increased between 240 and 300 min when compared with baseline ( P 0.05) only with MDX but not with inulin
Is medical supervision important during GLP-1 treatment
Switching to a different GLP-1 medication represents a reasonable first-line strategy